Pinar Yıldız Gülhan1, Ege Güleç Balbay1, Merve Erçelik1, Şeyma Yıldız2, Mehmet Alper Yılmaz3. 1. Faculty of Medicine, Department of Chest Diseases, Düzce University, Düzce, Turkey. 2. Faculty of Medicine, Department of Internal Medicine, Gazi University, Ankara, Turkey. 3. Department of Internal Medicine, Izmir Tepecik Education and Research Hospital, Izmir, Turkey.
Abstract
Aim: To investigate the relationship between sarcoidosis and metabolic syndrome (MetS) and insulin resistance (IR).Method: In our study, 47 patients with sarcoidosis who applied to our outpatient clinic and 45 healthy individuals without chronic disease were included. All patients were evaluated for MetS according to the National Cholesterol Education Program's Adult Treatment Panel III (NCEP-ATP III) criteria. The presence of three of the five factors defined by ATP III for MetS was accepted as a diagnosis of MetS. IR is calculated using the HOMA-IR index. Results: The mean age of the 47 patients with sarcoidosis was 50.7 ± 12.2 years and the mean age of the 45 control groups was 42.9 ± 14.4 years. Almost 80% of the patients were diagnosed as stage 2 sarcoidosis. Distribution of the patients according to the use of steroid is; almost half of the patients (47%) received steroid previously or recently. Patients with sarcoidosis have a 7.66 relative risk for MetS, whereas they also have a 5.48 relative risk of insulin resistance development. Conclusion: This study shows that MetS is associated with increased sarcoidosis risk. MetS and IR diagnosis was higher in patients with sarcoidosis.
Aim: To investigate the relationship between sarcoidosis and metabolic syndrome (MetS) and insulin resistance (IR).Method: In our study, 47 patients with sarcoidosis who applied to our outpatient clinic and 45 healthy individuals without chronic disease were included. All patients were evaluated for MetS according to the National Cholesterol Education Program's Adult Treatment Panel III (NCEP-ATP III) criteria. The presence of three of the five factors defined by ATP III for MetS was accepted as a diagnosis of MetS. IR is calculated using the HOMA-IR index. Results: The mean age of the 47 patients with sarcoidosis was 50.7 ± 12.2 years and the mean age of the 45 control groups was 42.9 ± 14.4 years. Almost 80% of the patients were diagnosed as stage 2 sarcoidosis. Distribution of the patients according to the use of steroid is; almost half of the patients (47%) received steroid previously or recently. Patients with sarcoidosis have a 7.66 relative risk for MetS, whereas they also have a 5.48 relative risk of insulin resistance development. Conclusion: This study shows that MetS is associated with increased sarcoidosis risk. MetS and IR diagnosis was higher in patients with sarcoidosis.